RareStone’s narcolepsy therapy receives approval in China

The Chinese NMPA has granted approval for RareStone Group’s pitolisant to treat cataplexy in adult narcolepsy patients.

Jul 5, 2023 - 20:00

RareStone’s narcolepsy therapy receives approval in China

The Chinese NMPA has granted approval for RareStone Group’s pitolisant to treat cataplexy in adult narcolepsy patients.

Read the original article

Tags:

Previous Article

NHS to provide vision-saving drug to premature babies

Labcorp forms spin-off of Fortrea

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

Sanofi completes the $1.7bn acquisition of Inhibrx

Sanofi completes the $1.7bn acquisition of Inhibrx

May 31, 2024

Galecto downsizes by 70% following Phase II trial failure

Galecto downsizes by 70% following Phase II trial failure

Sep 27, 2023

EMA CHMP provides positive opinion for ViiV’s cabotegravir

EMA CHMP provides positive opinion for ViiV’s cabotegravir

Jul 25, 2023